Kailera Therapeutics filed for an IPO to fund its obesity pipeline, spotlighting ribupatide, a weekly GLP-1/GIP agonist in late-stage development. The company said ribupatide delivered about 18% average weight loss over 48 weeks in a China phase 3 trial, and it expects additional dose data and broader global phase 3 updates. The filing also indicates the startup has attracted substantial venture backing and holds significant cash for continued clinical work. For a field dominated by Eli Lilly and Novo Nordisk, Kailera’s move signals persistent investor appetite for next-generation anti-obesity combinations and differentiated dosing or tolerability profiles. Market participants will likely track whether the IPO supports speed-to-readout and whether Kailera can carve out a competitive position on efficacy, safety, and long-term adherence versus current market leaders.